Scientific publications
Is there a role for HIPEC in ovarian cancer?
Harter P (1), du Bois A (2), Sehouli J (3), Mahner S (4), Vergote I (5), Chiva L (6), Gonzalez-Martin A (7), Fotopoulou C (3,8).
ABSTRACT
Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this.
Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and inconsistent results while some studies even report harm to the patients from a higher morbidity.
On this ground, we cannot recommend the implementation and use of HIPEC outside of a randomized clinical trial setting.
CITATION Arch Gynecol Obstet. 2018 Sep 20. doi: 10.1007/s00404-018-4908-0.
Our authors
